Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients

Contributed by: Business Wire

Logo

Tags

Research

Technology

Clinical Trials

Software

Biotechnology

Pharmaceutical

Health

Science

Oncology

Artificial Intelligence

Proscia

More Like This

Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

K Navigator home screen.

Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x

Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas